MCID: ORL015
MIFTS: 57

Oral Squamous Cell Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Gastrointestinal diseases

Aliases & Classifications for Oral Squamous Cell Carcinoma

Aliases & Descriptions for Oral Squamous Cell Carcinoma:

Name: Oral Squamous Cell Carcinoma 12 50 14
Squamous Cell Carcinoma of Mouth 69
Mouth Squamous Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050866

Summaries for Oral Squamous Cell Carcinoma

Disease Ontology : 12 An oral cavity cancer that has material basis in squamous cells.

MalaCards based summary : Oral Squamous Cell Carcinoma, also known as squamous cell carcinoma of mouth, is related to squamous cell carcinoma and leukoplakia. An important gene associated with Oral Squamous Cell Carcinoma is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Cetuximab and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and bone, and related phenotypes are Decreased viability and cardiovascular system

Related Diseases for Oral Squamous Cell Carcinoma

Diseases related to Oral Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 232)
id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 11.3
2 leukoplakia 10.5
3 endotheliitis 10.5
4 oral leukoplakia 10.5
5 spondylarthropathy 10.4 CDKN2A HRAS TP53
6 postpoliomyelitis syndrome 10.4 CDKN2A HRAS TP53
7 linitis plastica 10.4 CDH1 TP53
8 coronary stenosis 10.4 CDKN1B TP53 VEGFA
9 gallbladder pleomorphic giant cell adenocarcinoma 10.4 CDKN2A HRAS TP53
10 adult epithelioid sarcoma 10.4 CDKN2A HRAS TP53
11 oro-mandibular-limb hypogenesis syndrome 10.4 CCND1 CDKN2A TP53
12 brain stem medulloblastoma 10.4 CCND1 CDKN2A TP53
13 stenosis of lacrimal punctum 10.4 CCND1 EGFR HRAS
14 cervical verrucous carcinoma 10.4 CCND1 CDKN2A TP53
15 precursor t-lymphoblastic lymphoma/leukemia 10.4 EGFR HRAS PDPN
16 spastic paraplegia 1 10.4 EGFR TP53 VEGFA
17 aortic aneurysm 10.4 CDKN2A VEGFA VEGFC
18 aicardi-goutieres syndrome 10.4 CDKN2A HRAS TP53
19 brachydactyly tibial hypoplasia 10.4 CCND1 CDKN2A PTGS2
20 active vestibular meniere's disease 10.4 CCND1 CDKN2A PTGS2
21 facio skeletal genital syndrome rippberger type 10.4 MMP2 MMP9
22 chronic monocytic leukemia 10.4 CDKN2A EGFR TP53
23 thymus adenocarcinoma 10.4 EGFR MMP2 MMP9
24 acquired hemangioma 10.4 CDKN2A PTGS2 TP53
25 thymus squamous cell carcinoma 10.4 CDKN2A EGFR TP53
26 urethral verrucous carcinoma 10.4 CDKN2A PTGS2 TP53
27 chondrodysplasia punctata, rhizomelic, type 1 10.4 CDH1 MMP9 PTGS2
28 tumor of exocrine pancreas 10.4 CDKN2A EGFR VEGFA
29 secondary hyperparathyroidism of renal origin 10.4 CDKN2A EGFR TP53
30 anal carcinoma in situ 10.4 CDKN2A KRT19 TP53
31 clear cell adenofibroma 10.4 CDKN2A TP53
32 placental site trophoblastic tumor 10.4 CDKN2A TP53 VEGFA
33 large cell medulloblastoma 10.4 CTNNB1 MMP9 VEGFA
34 myxedema 10.4 CDKN2A EGFR HRAS TP53
35 breast papillary carcinoma 10.4 CDH1 MMP2 MMP9
36 tricuspid valve prolapse 10.4 CDKN2A EGFR PTGS2
37 papillary adenofibroma 10.4 HRAS KRT19 TP53
38 immunodeficiency due to a late component of complement deficiency 10.4 EGFR TP53 VEGFA
39 pityriasis rosea 10.4 CDKN1B CDKN2A EGFR TP53
40 pyomyositis 10.4 CDH1 CDKN2A EGFR TP53
41 interstitial lung disease 10.4 CDKN2A EGFR TP53 VEGFA
42 onychocytic matricoma 10.4 MMP2 MMP9 VEGFA
43 adenoid squamous cell carcinoma 10.4 CDKN2A MMP2 MMP9
44 spinal meninges cancer 10.4 CTNNB1 MMP2 MMP9
45 extraocular retinoblastoma 10.4 CCND1 CDKN1B CDKN2A TP53
46 tamoxifen-related endometrial lesion 10.4 CDKN2A PTGS2 TP53
47 integumentary system benign neoplasm 10.4 CCND1 CDKN1B CDKN2A TP53
48 cleft palate cardiac defect ectrodactyly 10.4 CCND1 EGFR TP53 VEGFA
49 post-surgical hypoinsulinemia 10.4 CCND1 CDKN1B CDKN2A TP53
50 lacrimal gland adenoid cystic carcinoma 10.4 CDKN2A TP53

Graphical network of the top 20 diseases related to Oral Squamous Cell Carcinoma:



Diseases related to Oral Squamous Cell Carcinoma

Symptoms & Phenotypes for Oral Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.55 EGFR HRAS
2 Decreased viability GR00221-A-1 9.55 CDKN1B CDKN2A EGFR HRAS AKT1 CDH1
3 Decreased viability GR00221-A-2 9.55 HRAS AKT1
4 Decreased viability GR00221-A-3 9.55 CDKN2A HRAS AKT1
5 Decreased viability GR00221-A-4 9.55 CDKN2A EGFR AKT1
6 Decreased viability GR00301-A 9.55 CDH1
7 Decreased cell migration GR00055-A-1 9.35 AKT1 CTNNB1 EGFR HRAS VEGFC

MGI Mouse Phenotypes related to Oral Squamous Cell Carcinoma:

44 (show all 25)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.57 CTNNB1 EGFR HOPX HRAS KRT19 MMP2
2 homeostasis/metabolism MP:0005376 10.49 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
3 growth/size/body region MP:0005378 10.48 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
4 cellular MP:0005384 10.46 HOPX KRT19 MMP9 PTGS2 TP53 VEGFA
5 mortality/aging MP:0010768 10.46 HRAS KRT19 MMP2 MMP9 PDPN PTGS2
6 immune system MP:0005387 10.42 CDKN2A CTNNB1 EGFR MMP2 MMP9 PDPN
7 digestive/alimentary MP:0005381 10.41 CDKN1B CDKN2A CTNNB1 EGFR KRT19 MMP9
8 integument MP:0010771 10.41 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
9 behavior/neurological MP:0005386 10.4 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
10 endocrine/exocrine gland MP:0005379 10.4 CDH1 CDKN1B CDKN2A CTNNB1 EGFR HRAS
11 hematopoietic system MP:0005397 10.38 CCND1 CDKN1B CDKN2A CTNNB1 EGFR MMP2
12 neoplasm MP:0002006 10.32 AKT1 CCND1 CDH1 CDKN1B CDKN2A CTNNB1
13 muscle MP:0005369 10.31 AKT1 CASP3 CDKN1B CDKN2A CTNNB1 EGFR
14 nervous system MP:0003631 10.3 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
15 embryo MP:0005380 10.29 TP53 VEGFA AKT1 CDH1 CDKN2A CTNNB1
16 craniofacial MP:0005382 10.26 CASP3 CCND1 CDKN1B CTNNB1 EGFR HRAS
17 no phenotypic analysis MP:0003012 10.21 PTGS2 TP53 VEGFA CASP3 CDH1 CDKN1B
18 normal MP:0002873 10.14 AKT1 CCND1 CDH1 CTNNB1 EGFR HRAS
19 liver/biliary system MP:0005370 10.13 AKT1 CDKN1B CDKN2A CTNNB1 EGFR PTGS2
20 reproductive system MP:0005389 10.07 MMP9 PTGS2 TP53 VEGFA AKT1 CASP3
21 respiratory system MP:0005388 10.03 CDKN1B CDKN2A CTNNB1 EGFR HOPX HRAS
22 renal/urinary system MP:0005367 9.97 CASP3 CDKN1B CTNNB1 EGFR HRAS MMP9
23 pigmentation MP:0001186 9.85 CASP3 CDKN1B CDKN2A CTNNB1 EGFR TP53
24 skeleton MP:0005390 9.83 AKT1 CASP3 CCND1 CDKN1B CDKN2A CTNNB1
25 vision/eye MP:0005391 9.36 CDKN2A CTNNB1 EGFR MMP2 MMP9 PTGS2

Drugs & Therapeutics for Oral Squamous Cell Carcinoma

Drugs for Oral Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cetuximab Approved Phase 4,Phase 2,Phase 3,Phase 1 205923-56-4 56842117 2333
2
Fluorouracil Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-21-8 3385
3
Cevimeline Approved Phase 4,Phase 3 107233-08-9 83898 25137844
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
5
Technetium tc 99m sulfur colloid Approved Phase 4
6
Everolimus Approved Phase 4,Phase 1,Phase 2 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
9
Morphine Approved, Investigational Phase 4 57-27-2 5288826
10
Edetic Acid Approved, Vet_approved Phase 4 60-00-4, 62-33-9 6049
11
Azathioprine Approved Phase 4 446-86-6 2265
12
Cyclosporine Approved, Investigational, Vet_approved Phase 4 79217-60-0, 59865-13-3 5284373 6435893
13
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
14
Mycophenolic acid Approved Phase 4 24280-93-1 446541
15
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
16 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Cholinergic Agents Phase 4,Phase 3
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1
24 Antimetabolites, Antineoplastic Phase 4,Phase 2,Phase 3,Phase 1
25 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
26 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
27 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
28 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Mitomycins Phase 4,Phase 3,Phase 2
33 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 1
34 Analgesics, Opioid Phase 4,Phase 3
35 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
36 Anesthetics, General Phase 4,Phase 3,Phase 1
37 Anesthetics, Intravenous Phase 4,Phase 3,Phase 1
38 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Narcotics Phase 4,Phase 3
40 Radiopharmaceuticals Phase 4,Phase 1,Phase 2
41 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Anticoagulants Phase 4
43 Blood Substitutes Phase 4
44 Chelating Agents Phase 4
45 Dextrans Phase 4
46 Pentetic Acid Phase 4
47 Plasma Substitutes Phase 4
48 Technetium Tc 99m Pentetate Phase 4
49 Calcineurin Inhibitors Phase 4
50 arginine Nutraceutical Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 758)
id Name Status NCT ID Phase
1 Study of the Effectiveness of Cevimeline on Oral Health in Patients With Radiation Induced Xerostomia Completed NCT00466388 Phase 4
2 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
3 Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients Completed NCT02622880 Phase 4
4 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
5 Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Recruiting NCT02015650 Phase 4
6 Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy Recruiting NCT02869321 Phase 4
7 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4
8 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
9 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4
10 TPF Induction Chemotherapy for Locally Advanced and Resectable Oral Squamous Cell Carcinoma Unknown status NCT01542931 Phase 2, Phase 3
11 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
12 Oral Cancer Adjuvant Therapy (OCAT) Trial Unknown status NCT00193843 Phase 3
13 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3
14 Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer Unknown status NCT00002747 Phase 3
15 Surgery and Radiation Therapy With or Without Interleukin-2 in Treating Patients With Cancer of the Mouth or Oropharynx Unknown status NCT00002702 Phase 3
16 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Unknown status NCT01434394 Phase 2, Phase 3
17 Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment Unknown status NCT00935675 Phase 3
18 S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer Unknown status NCT00336947 Phase 3
19 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3
20 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
21 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
22 Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3
23 Chemoprevention Study of Oral Cavity Squamous Cell Carcinoma Completed NCT00201279 Phase 3
24 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
25 Phase II Trial of Allovectin-7® for Head and Neck Cancer Completed NCT00050388 Phase 3
26 LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy Completed NCT01345682 Phase 3
27 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3
28 Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00003139 Phase 3
29 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3
30 Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3
31 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Completed NCT00101582 Phase 3
32 Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00771641 Phase 3
33 Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery Completed NCT00424255 Phase 3
34 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
35 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3
36 Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery Completed NCT00002670 Phase 3
37 Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00054561 Phase 3
38 Biafine Cream to Reduce Side Effects of Radiation Therapy in Patients Receiving Treatment for Advanced Head and Neck Cancer Completed NCT00006481 Phase 3
39 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003888 Phase 3
40 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3
41 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3
42 Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00003809 Phase 3
43 Surgery and Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer That Can Be Removed During Surgery Completed NCT00003576 Phase 3
44 Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer Completed NCT00064298 Phase 3
45 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
46 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3
47 Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer Completed NCT00608205 Phase 3
48 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3
49 Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck Cancer Completed NCT00094081 Phase 3
50 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3

Search NIH Clinical Center for Oral Squamous Cell Carcinoma

Genetic Tests for Oral Squamous Cell Carcinoma

Anatomical Context for Oral Squamous Cell Carcinoma

MalaCards organs/tissues related to Oral Squamous Cell Carcinoma:

39
Lymph Node, Endothelial, Bone, T Cells, Neutrophil, Tongue, Testes

Publications for Oral Squamous Cell Carcinoma

Articles related to Oral Squamous Cell Carcinoma:

(show top 50) (show all 2103)
id Title Authors Year
1
Long non-coding RNA FTH1P3 facilitates oral squamous cell carcinoma progression by acting as a molecular sponge of miR-224-5p to modulate fizzled 5 expression. ( 28093311 )
2017
2
Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling. ( 28085115 )
2017
3
Isomahanine induces endoplasmic reticulum stress and simultaneously triggers p38A MAPK-mediated apoptosis and autophagy in multidrug-resistant human oral squamous cell carcinoma cells. ( 28075474 )
2017
4
Role of microscopic spread beyond gross disease as an adverse prognostic factor in oral squamous cell carcinoma. ( 28528911 )
2017
5
Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells. ( 27889233 )
2017
6
Histone deacetylase 8 as a novel therapeutic target in oral squamous cell carcinoma. ( 28004115 )
2017
7
A comprehensive analysis of candidate gene signatures in oral squamous cell carcinoma. ( 28043142 )
2017
8
The circadian clock gene PER2 plays an important role in tumor suppression through regulating tumor-associated genes in human oral squamous cell carcinoma. ( 28535015 )
2017
9
Combined Analysis of Vascular Endothelial Growth Factor Expression with Cyclooxygenase-2 and Mast Cell Density in Oral Squamous Cell Carcinoma. ( 27577989 )
2017
10
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. ( 28314313 )
2017
11
High HMGA2 Expression Correlates with Reduced Recurrence-free Survival and Poor Overall Survival in Oral Squamous Cell Carcinoma. ( 28373457 )
2017
12
High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens. ( 26590596 )
2017
13
Upregulated Expression of Transient Receptor Potential Cation Channel Subfamily V Receptors in Mucosae of Patients with Oral Squamous Cell Carcinoma and Patients with a History of Alcohol Consumption or Smoking. ( 28081185 )
2017
14
Transcriptome analysis reveals differentially expressed lncRNAs between oral squamous cell carcinoma and healthy oral mucosa. ( 28415559 )
2017
15
Transforming growth factor-I^1 suppresses bone morphogenetic protein-2-induced mesenchymal-epithelial transition in HSC-4 human oral squamous cell carcinoma cells via Smad1/5/9 pathway suppression. ( 28035402 )
2017
16
Saliva protein biomarkers and oral squamous cell carcinoma. ( 28039438 )
2017
17
Long noncoding RNA HAS2-AS1 mediates hypoxia-induced invasiveness of oral squamous cell carcinoma. ( 28485478 )
2017
18
Paraoxonase 3 promotes cell proliferation and metastasis by PI3K/Akt in oral squamous cell carcinoma. ( 27923688 )
2017
19
LncRNA, TUG1 regulates the oral squamous cell carcinoma progression possibly via interacting with Wnt/I^-catenin signaling. ( 28119088 )
2017
20
KLK4 silencing inhibits the growth of oral squamous cell carcinoma through Wnt/I^-catenin signaling pathway. ( 28150891 )
2017
21
Expression of hypoxia-induced factor-1 alpha in early-stage and in metastatic oral squamous cell carcinoma. ( 28381176 )
2017
22
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. ( 27922697 )
2017
23
Downregulation of miR-377 Promotes Oral Squamous Cell Carcinoma Growth and Migration by Targeting HDAC9. ( 28267394 )
2017
24
The expression and significance of the HOXA7 gene in oral squamous cell carcinoma. ( 28529281 )
2017
25
Saliva protein biomarkers to detect oral squamous cell carcinoma in a high-risk population in Taiwan. ( 27663741 )
2016
26
Expression profiles of MGMT, p16, and APC genes in tumor and matching surgical margin from patients with oral squamous cell carcinoma. ( 27494112 )
2016
27
Nucleotide-binding oligomerization domain 2 (NOD2) activation induces apoptosis of human oral squamous cell carcinoma cells. ( 26332444 )
2016
28
Clinicopathological implications of vascular endothelial growth factor 165b expression in oral squamous cell carcinoma stroma. ( 27221145 )
2016
29
Recruitment of Tiam1 to Semaphorin 4D Activates Rac and Enhances Proliferation, Invasion, and Metastasis in Oral Squamous Cell Carcinoma. ( 28038319 )
2016
30
Overexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosis. ( 26992905 )
2016
31
Detection of survivin, carcinoembryonic antigen and Erbb2 level in oral squamous cell carcinoma patients. ( 27662323 )
2016
32
Overexpression of proteasomal activator PA28I+ serves as a prognostic factor in oral squamous cell carcinoma. ( 26892607 )
2016
33
MALDI imaging reveals NCOA7 as a potential biomarker in oral squamous cell carcinoma arising from oral submucous fibrosis. ( 27509054 )
2016
34
Association of the XPD and XRCC3 gene polymorphisms with oral squamous cell carcinoma in a Northeastern Brazilian population: A pilot study. ( 26742000 )
2016
35
Adenosine Deaminase - a Novel Diagnostic and Prognostic Biomarker for Oral Squamous Cell Carcinoma. ( 27221867 )
2016
36
Micronome revealed miR-19a/b as key regulator of SOCS3 during cancer related inflammation of oral squamous cell carcinoma. ( 27581787 )
2016
37
Signal regulatory protein I+ associated with the progression of oral leukoplakia and oral squamous cell carcinoma regulates phenotype switch of macrophages. ( 27793032 )
2016
38
Crosstalk between the HIF-1 and toll-like receptor/nuclear factor-I_B pathways in the oral squamous cell carcinoma microenvironment. ( 27191981 )
2016
39
Salivary Levels of ErbB2 and CEA in Oral Squamous Cell Carcinoma Patients. ( 27165212 )
2016
40
Validation of housekeeping genes for the normalization of RT-qPCR expression studies in oral squamous cell carcinoma cell line treated by 5 kinds of chemotherapy drugs. ( 28040059 )
2016
41
Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas. ( 26636434 )
2016
42
Genome-wide haplotype association analysis identifies SERPINB9, SERPINE2, GAK, and HSP90B1 as novel risk genes for oral squamous cell carcinoma. ( 26318431 )
2016
43
Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression. ( 26211876 )
2016
44
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population. ( 27644669 )
2016
45
Is an Elective Neck Dissection Necessary for All Cases of N0 Oral Squamous Cell Carcinoma? -Elective Neck Dissection may be Performed for Tongue Cancer with Tumor Thickness More than 4 mm. ( 27628601 )
2016
46
Overexpression of I^-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma. ( 27529071 )
2016
47
Tachykinin Receptor 3 Distribution in Human Oral Squamous Cell Carcinoma. ( 27919954 )
2016
48
Absence of high-risk HPV 16 and 18 in Chinese patients with oral squamous cell carcinoma and oral potentially malignant disorders. ( 27206495 )
2016
49
Immunohistochemical Evaluation of Mast Cells in Leukoplakia and Oral Squamous Cell Carcinoma. ( 27656549 )
2016
50
Hypoxia inducible factor: a potential prognostic biomarker in oral squamous cell carcinoma. ( 26880584 )
2016

Variations for Oral Squamous Cell Carcinoma

Cosmic variations for Oral Squamous Cell Carcinoma:

9 (show top 50) (show all 434)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3724309 ZNF536 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1935G>C p.Q645H 12
2 COSM44310 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.738G>A p.M246I 12
3 COSM10648 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.524G>A p.R175H 12
4 COSM11196 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.734G>T p.G245V 12
5 COSM43947 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.614A>G p.Y205C 12
6 COSM44393 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.821T>C p.V274A 12
7 COSM43582 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.454C>T p.P152S 12
8 COSM44226 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.380C>T p.S127F 12
9 COSM10654 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.637C>T p.R213* 12
10 COSM10704 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.844C>T p.R282W 12
11 COSM10672 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.577C>T p.H193Y 12
12 COSM10941 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.730G>A p.G244S 12
13 COSM10656 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.742C>T p.R248W 12
14 COSM10728 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.839G>A p.R280K 12
15 COSM43635 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>T p.H179L 12
16 COSM44126 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.507G>A p.M169I 12
17 COSM10790 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.455C>T p.P152L 12
18 COSM43868 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.689C>T p.T230I 12
19 COSM44335 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.958A>T p.K320* 12
20 COSM44091 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.746G>A p.R249K 12
21 COSM11063 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>T p.M237I 12
22 COSM44577 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.921A>G p.A307A 12
23 COSM10834 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>A p.M237I 12
24 COSM45099 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.924G>A p.L308L 12
25 COSM10867 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.797G>A p.G266E 12
26 COSM11073 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.1024C>T p.R342* 12
27 COSM44428 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.741C>T p.N247N 12
28 COSM43621 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.809T>G p.F270C 12
29 COSM10663 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.916C>T p.R306* 12
30 COSM10886 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 12
31 COSM10660 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.818G>A p.R273H 12
32 COSM10726 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.856G>A p.E286K 12
33 COSM45046 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.542G>C p.R181P 12
34 COSM44415 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.711G>C p.M237I 12
35 COSM10756 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.827C>T p.A276V 12
36 COSM45607 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.676G>A p.G226S 12
37 COSM43714 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.836G>A p.G279E 12
38 COSM43743 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.914A>G p.K305R 12
39 COSM10662 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 12
40 COSM10659 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.817C>T p.R273C 12
41 COSM10810 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.725G>T p.C242F 12
42 COSM10905 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.451C>T p.P151S 12
43 COSM44894 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.874A>T p.K292* 12
44 COSM45353 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.673G>A p.V225I 12
45 COSM43801 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.716A>C p.N239T 12
46 COSM43632 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.493C>T p.Q165* 12
47 COSM10891 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.814G>A p.V272M 12
48 COSM45077 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.390C>T p.L130L 12
49 COSM10889 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.536A>G p.H179R 12
50 COSM44639 TP53 upper aerodigestive tract,mouth,carcinoma,squamous cell carcinoma c.869G>T p.R290L 12

Copy number variations for Oral Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 164)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 41848 10 24600000 38000000 Deletion Oral squamous cell carcinoma
2 49706 11 110400000 121200000 Deletion Oral squamous cell carcinoma
3 50988 11 121200000 130800000 Deletion Oral squamous cell carcinoma
4 51497 11 12700000 16200000 Deletion Oral squamous cell carcinoma
5 57445 11 63400000 77100000 Amplification CCND1 Oral squamous cell carcinoma
6 57446 11 63400000 77100000 Amplification EMS1 Oral squamous cell carcinoma
7 57448 11 63400000 77100000 Amplification FGF3 Oral squamous cell carcinoma
8 57449 11 63400000 77100000 Amplification FGF4 Oral squamous cell carcinoma
9 57450 11 63400000 77100000 Amplification PPP1CA Oral squamous cell carcinoma
10 57451 11 63400000 77100000 Amplification TAOS1 Oral squamous cell carcinoma
11 58782 11 69471367 69490165 Amplification ORAOV1 Oral squamous cell carcinoma
12 74065 13 1 4500000 Deletion Oral squamous cell carcinoma
13 74179 13 101700000 110300000 Deletion Oral squamous cell carcinoma
14 75170 13 17900000 115169878 Noncopy numberrandom LOH Oral squamous cell carcinoma
15 76133 13 27800000 55300000 Deletion Oral squamous cell carcinoma
16 76134 13 27800000 87700000 Deletion Oral squamous cell carcinoma
17 76220 13 28900000 40100000 Deletion Oral squamous cell carcinoma
18 76534 13 32200000 40100000 Deletion Oral squamous cell carcinoma
19 76709 13 35500000 40100000 Deletion Oral squamous cell carcinoma
20 77109 13 40100000 59600000 Deletion Oral squamous cell carcinoma
21 78640 13 55300000 73300000 Deletion Oral squamous cell carcinoma
22 79281 13 68600000 87700000 Deletion Oral squamous cell carcinoma
23 79539 13 73300000 79000000 Deletion Oral squamous cell carcinoma
24 79879 13 79000000 87700000 Deletion Oral squamous cell carcinoma
25 80342 13 90000000 98200000 Deletion Oral squamous cell carcinoma
26 80629 13 95000000 110300000 Deletion Oral squamous cell carcinoma
27 80632 13 95000000 115169878 Deletion Oral squamous cell carcinoma
28 80634 13 95000000 98200000 Deletion Oral squamous cell carcinoma
29 83034 14 19100000 33300000 Deletion Oral squamous cell carcinoma
30 84231 14 24600000 33300000 Deletion Oral squamous cell carcinoma
31 85052 14 37800000 50900000 Deletion Oral squamous cell carcinoma
32 86340 14 58100000 67900000 Deletion Oral squamous cell carcinoma
33 86341 14 58100000 73800000 Deletion Oral squamous cell carcinoma
34 87452 14 73800000 79300000 Deletion Oral squamous cell carcinoma
35 89133 15 1 19000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
36 90246 15 20700000 40100000 Deletion Oral squamous cell carcinoma
37 91779 15 33600000 40100000 Deletion Oral squamous cell carcinoma
38 91783 15 33600000 44800000 Deletion Oral squamous cell carcinoma
39 92363 15 40100000 49500000 Deletion Oral squamous cell carcinoma
40 92861 15 44800000 49500000 Deletion Oral squamous cell carcinoma
41 93371 15 52900000 72700000 Deletion Oral squamous cell carcinoma
42 95627 15 78300000 89100000 Deletion Oral squamous cell carcinoma
43 95629 15 78300000 98500000 Deletion Oral squamous cell carcinoma
44 106754 17 1 16000000 Deletion Oral squamous cell carcinoma
45 106831 17 1 24000000 Noncopy numberrandom LOH Oral squamous cell carcinoma
46 106907 17 1 81195210 Deletion Oral squamous cell carcinoma
47 106970 17 10700000 50200000 Deletion Oral squamous cell carcinoma
48 109058 17 24000000 81195210 Noncopy numberrandom LOH Oral squamous cell carcinoma
49 112186 17 38100000 57600000 Deletion Oral squamous cell carcinoma
50 114590 17 50200000 70900000 Deletion Oral squamous cell carcinoma

Expression for Oral Squamous Cell Carcinoma

Search GEO for disease gene expression data for Oral Squamous Cell Carcinoma.

Pathways for Oral Squamous Cell Carcinoma

Pathways related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 135)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.17 AKT1 CASP3 CCND1 CDH1 CDKN1B CTNNB1
2
Show member pathways
13.98 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
3
Show member pathways
13.85 AKT1 CCND1 CDKN1B CDKN2A EGFR HRAS
4
Show member pathways
13.62 AKT1 CTNNB1 EGFR HRAS KRT19 MMP2
5
Show member pathways
13.53 AKT1 CASP3 CTNNB1 EGFR HRAS MMP2
6
Show member pathways
13.53 AKT1 CASP3 CCND1 CDKN1B EGFR HRAS
7
Show member pathways
13.49 AKT1 CASP3 CCND1 EGFR HRAS MMP2
8
Show member pathways
13.41 AKT1 CASP3 CDH1 CTNNB1 EGFR HRAS
9
Show member pathways
13.41 AKT1 CASP3 CDH1 CTNNB1 EGFR HRAS
10
Show member pathways
13.13 AKT1 CASP3 CDH1 CTNNB1 HRAS TP53
11
Show member pathways
13.11 AKT1 CCND1 CDH1 CDKN1B CDKN2A CTNNB1
12
Show member pathways
13.05 AKT1 CASP3 CCND1 CDKN1B HRAS MMP9
13
Show member pathways
13.03 AKT1 CDKN2A EGFR HRAS MMP9 PTGS2
14
Show member pathways
13.03 AKT1 CCND1 CDKN1B CTNNB1 EGFR HRAS
15
Show member pathways
13.02 AKT1 CASP3 CTNNB1 HRAS MMP9 TP53
16
Show member pathways
12.94 AKT1 CASP3 CDH1 CTNNB1 HRAS PTGS2
17
Show member pathways
12.93 AKT1 CASP3 CCND1 CTNNB1 EGFR HRAS
18
Show member pathways
12.88 AKT1 CDH1 CTNNB1 EGFR HRAS VEGFA
19
Show member pathways
12.83 AKT1 CDKN1B EGFR HRAS TP53
20 12.82 AKT1 CASP3 EGFR HRAS TP53
21
Show member pathways
12.78 AKT1 CTNNB1 MMP2 MMP9 VEGFA
22
Show member pathways
12.78 AKT1 CASP3 EGFR HRAS TP53
23
Show member pathways
12.74 AKT1 CTNNB1 EGFR HRAS MMP2 TP53
24
Show member pathways
12.73 AKT1 CASP3 HRAS VEGFA VEGFC
25 12.73 AKT1 CCND1 CDKN1B EGFR HRAS TP53
26
Show member pathways
12.69 AKT1 CCND1 CDKN1B CDKN2A TP53
27 12.63 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
28
Show member pathways
12.6 AKT1 CASP3 CTNNB1 EGFR HRAS TP53
29 12.58 AKT1 CCND1 CDH1 CTNNB1 PTGS2 TP53
30 12.58 AKT1 CCND1 CDKN2A CTNNB1 HRAS TP53
31 12.58 CASP3 CCND1 CDKN1B CDKN2A EGFR HRAS
32
Show member pathways
12.56 CCND1 CDKN1B CTNNB1 EGFR HRAS
33
Show member pathways
12.56 AKT1 CASP3 CCND1 CDH1 CDKN1B CTNNB1
34
Show member pathways
12.54 CASP3 EGFR HRAS VEGFA VEGFC
35
Show member pathways
12.54 AKT1 CTNNB1 HRAS PTGS2 VEGFA
36
Show member pathways
12.54 AKT1 CCND1 CDKN1B HRAS TP53
37
Show member pathways
12.52 AKT1 CASP3 CCND1 CDH1 CTNNB1 EGFR
38
Show member pathways
12.51 CASP3 CCND1 CDKN1B CDKN2A TP53
39 12.51 CCND1 CDH1 CDKN1B CDKN2A TP53
40
Show member pathways
12.51 AKT1 EGFR HRAS VEGFA VEGFC
41
Show member pathways
12.47 AKT1 CCND1 CDKN1B EGFR HRAS TP53
42
Show member pathways
12.46 CCND1 CDKN1B CDKN2A TP53
43
Show member pathways
12.46 AKT1 CCND1 EGFR HRAS PTGS2
44 12.45 CASP3 CCND1 CDKN1B CDKN2A HRAS TP53
45
Show member pathways
12.43 AKT1 CASP3 MMP9 PTGS2
46
Show member pathways
12.43 AKT1 CCND1 CTNNB1 HRAS
47
Show member pathways
12.42 AKT1 CASP3 CDKN1B HRAS TP53 VEGFA
48
Show member pathways
12.38 AKT1 EGFR HRAS VEGFA VEGFC
49
Show member pathways
12.37 AKT1 CASP3 CCND1 TP53
50
Show member pathways
12.34 AKT1 CASP3 CCND1 CDKN1B EGFR TP53

GO Terms for Oral Squamous Cell Carcinoma

Cellular components related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A
2 catenin complex GO:0016342 9.16 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.96 CDH1 CTNNB1

Biological processes related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell migration GO:0030335 9.96 EGFR HRAS MMP9 VEGFA
2 cell cycle arrest GO:0007050 9.92 CDKN1B CDKN2A HRAS TP53
3 response to hypoxia GO:0001666 9.92 CASP3 CDKN1B MMP2 VEGFA VEGFC
4 positive regulation of apoptotic process GO:0043065 9.91 AKT1 CASP3 CDKN2A CTNNB1 MMP9 PTGS2
5 cellular response to hypoxia GO:0071456 9.9 AKT1 PTGS2 TP53 VEGFA
6 extracellular matrix disassembly GO:0022617 9.89 CDH1 MMP2 MMP9
7 G1/S transition of mitotic cell cycle GO:0000082 9.89 AKT1 CCND1 CDKN1B CDKN2A
8 cellular response to mechanical stimulus GO:0071260 9.88 AKT1 EGFR PTGS2
9 cellular response to organic cyclic compound GO:0071407 9.88 AKT1 CASP3 CDKN1B
10 lung development GO:0030324 9.88 CTNNB1 EGFR PDPN VEGFA
11 response to organic cyclic compound GO:0014070 9.88 CASP3 CCND1 CDKN1B EGFR PTGS2
12 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.87 AKT1 PTGS2 VEGFA
13 response to glucocorticoid GO:0051384 9.87 CASP3 CCND1 PTGS2
14 response to drug GO:0042493 9.87 CASP3 CCND1 CDH1 CDKN1B CTNNB1 PTGS2
15 Ras protein signal transduction GO:0007265 9.86 CDKN2A HRAS TP53
16 positive regulation of endothelial cell proliferation GO:0001938 9.86 AKT1 VEGFA VEGFC
17 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.86 AKT1 PTGS2 VEGFA
18 positive regulation of cell proliferation GO:0008284 9.86 CCND1 CDKN1B CTNNB1 EGFR HRAS PTGS2
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.85 AKT1 EGFR PTGS2
20 positive regulation of MAP kinase activity GO:0043406 9.85 EGFR HRAS VEGFA
21 cellular response to growth factor stimulus GO:0071363 9.84 AKT1 CTNNB1 EGFR
22 single organismal cell-cell adhesion GO:0016337 9.83 CDH1 CRNN CTNNB1 EGFR PDPN
23 positive regulation of neuron apoptotic process GO:0043525 9.82 CASP3 CTNNB1 TP53
24 embryo implantation GO:0007566 9.81 MMP2 MMP9 PTGS2
25 positive regulation of epithelial cell proliferation GO:0050679 9.81 EGFR HRAS VEGFA VEGFC
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.8 AKT1 EGFR PTGS2
27 response to organic substance GO:0010033 9.8 AKT1 CASP3 CCND1 CDH1 PTGS2
28 positive regulation of vasoconstriction GO:0045907 9.79 AKT1 EGFR PTGS2
29 cellular response to reactive oxygen species GO:0034614 9.79 AKT1 EGFR MMP9
30 cellular response to cadmium ion GO:0071276 9.78 AKT1 EGFR MMP9
31 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.75 CASP3 CDKN1B CDKN2A
32 response to X-ray GO:0010165 9.74 CASP3 CCND1 TP53
33 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 AKT1 VEGFA VEGFC
34 positive regulation of neuroblast proliferation GO:0002052 9.72 CTNNB1 VEGFA VEGFC
35 positive regulation of cellular component movement GO:0051272 9.7 PDPN VEGFA
36 mitotic G1 DNA damage checkpoint GO:0031571 9.69 CCND1 TP53
37 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.67 AKT1 EGFR
38 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.67 PTGS2 VEGFA
39 positive regulation of mast cell chemotaxis GO:0060754 9.65 VEGFA VEGFC
40 cellular response to indole-3-methanol GO:0071681 9.64 CDH1 CTNNB1
41 positive regulation of protein phosphorylation GO:0001934 9.63 AKT1 CCND1 EGFR HRAS MMP9 VEGFA
42 response to UV-A GO:0070141 9.13 AKT1 CCND1 EGFR
43 response to estradiol GO:0032355 9.1 CASP3 CCND1 CDKN1B CTNNB1 EGFR PTGS2
44 multicellular organism development GO:0007275 10.22 AKT1 EGFR HOPX PDPN TP53 VEGFA
45 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.2 AKT1 CDKN2A CTNNB1 EGFR HRAS TP53
46 positive regulation of transcription, DNA-templated GO:0045893 10.11 AKT1 CDH1 CDKN2A CTNNB1 EGFR TP53
47 negative regulation of apoptotic process GO:0043066 10.04 AKT1 CASP3 CDKN1B EGFR MMP9 TP53
48 regulation of cell proliferation GO:0042127 10.01 CDKN1B CTNNB1 EGFR PTGS2
49 cell proliferation GO:0008283 10.01 AKT1 CTNNB1 EGFR HRAS PDPN TP53
50 angiogenesis GO:0001525 10 MMP2 PTGS2 VEGFA VEGFC

Molecular functions related to Oral Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.73 AKT1 CCND1 CTNNB1 EGFR PTGS2 TP53
2 protein phosphatase binding GO:0019903 9.46 CDKN1B CTNNB1 EGFR TP53
3 nitric-oxide synthase regulator activity GO:0030235 9.37 AKT1 EGFR
4 protein kinase binding GO:0019901 9.17 AKT1 CCND1 CDKN1B CDKN2A CTNNB1 EGFR
5 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.13 CASP3 CDKN1B CDKN2A
6 protein binding GO:0005515 10.28 AKT1 CASP3 CCND1 CDH1 CDKN1B CDKN2A

Sources for Oral Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....